Tenax Therapeutics (NASDAQ:TENX) Issues Earnings Results, Beats Expectations By $0.34 EPS

Tenax Therapeutics (NASDAQ:TENX) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.34, Zacks reports.

Tenax Therapeutics Price Performance

Tenax Therapeutics stock opened at $6.26 on Wednesday. The stock has a fifty day moving average of $6.44 and a 200-day moving average of $5.39. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $7.89.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on TENX shares. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research note on Monday, March 10th. Finally, StockNews.com began coverage on shares of Tenax Therapeutics in a research report on Friday, March 21st. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Tenax Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.